Hims & Hers Health Q2 2025: Navigating Contradictions in Weight Loss Strategy and AI Investments

Weight loss segment performance and strategy, GLP-1 personalization and transition strategy, GLP-1 subscriber growth and impact on revenue, AI investment and strategic focus are the key contradictions discussed in Hims & Hers Health's latest 2025Q2 earnings call.



Revenue and Subscriber Growth:
- Hims & Hers Health, Inc. reported revenue growth of 73% year-over-year to $545 million in Q2 2025, while subscribers increased by 73,000 quarter-over-quarter to over 2.4 million.
- This growth was driven by the demand for personalized and high-quality care in various specialties such as dermatology, oral weight loss, and daily sexual health.

Financial Performance and Margins:
- The company maintained an adjusted EBITDA margin north of 15%, with adjusted EBITDA reaching $82 million in Q2.
- The expansion of gross margins by 3 points quarter-over-quarter to 76% was a result of growth in specialties outside of weight loss and effective leveraging of marketing investments.

Investment in AI and Technology:
- Hims & Hers appointed a new Chief Technology Officer, Mo Elshenawy, to advance technological capabilities and drive AI adoption.
- The company plans to invest in AI-powered personalized agents, a multimodal architecture for international expansion, and AI governance to ensure ethical use of technology.

International Expansion and Acquisitions:
- The acquisition of ZAVA was completed to expand Hims & Hers' presence in the U.K. and other European markets, along with plans to enter Canada in 2026.
- The acquisition and regional expansion are aimed at tapping into the growing demand for personalized healthcare solutions in international markets.